Intellia Therapeutics, Inc.

Equities

NTLA

US45826J1051

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
26.22 ^USD	+1.90%		+14.00%	-14.00%

May. 09	Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises	MT
May. 09	Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024

Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023

May 04, 2023 at 07:41 am EDT

Intellia Therapeutics, Inc. reported earnings results for the first quarter ended March 31, 2023. For the first quarter, the company reported net loss was USD 103.13 million compared to USD 146.87 million a year ago. Basic loss per share from continuing operations was USD 1.17 compared to USD 1.96 a year ago.

Latest news about Intellia Therapeutics, Inc.

Intellia Therapeutics' Q1 Net Loss Narrows, Collaboration Revenue Rises	May. 09	MT
Transcript : Intellia Therapeutics, Inc., Q1 2024 Earnings Call, May 09, 2024	May. 09
Intellia Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	May. 09	CI
Intellia Therapeutics, Inc. Appoints Michael P. Dube as Principal Accounting Officer	Apr. 15	CI
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 25	MT
Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals	Mar. 22	MT
Intellia Therapeutics Ends Co-Development Agreement With Regeneron	Mar. 22	DJ
Intellia Therapeutics, Inc. Announces First Patient Dosed in Phase 3 MAGNITUDE Study of NTLA-2001 as Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy	Mar. 18	CI
Transcript : Intellia Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 03:05 PM	Mar. 13
North American Morning Briefing : Traders Await -2-	Feb. 26	DJ
Canaccord Genuity Adjusts Price Target on Intellia Therapeutics to $73 From $72, Maintains Buy Rating	Feb. 23	MT
Intellia Therapeutics Q4 Loss Widens	Feb. 22	MT
Transcript : Intellia Therapeutics, Inc., Q4 2023 Earnings Call, Feb 22, 2024	Feb. 22
Intellia Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 22	CI
Intellia Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 22	CI
Intellia Therapeutics, ReCode to Develop Therapies For Cystic Fibrosis	Feb. 15	MT
Wolfe Research Starts Intellia Therapeutics With Peer Perform Rating	Feb. 15	MT
Intellia Therapeutics, Inc. and ReCode Therapeutics Announces Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis	Feb. 15	CI
Intellia Therapeutics Says Investigational Hereditary Angioedema Treatment Shows Promise in Phase 1 Study	Feb. 01	MT
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine	Jan. 31	CI
Transcript : Intellia Therapeutics, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 05:15 PM	Jan. 09
Intellia Therapeutics Insider Sold Shares Worth $566,310, According to a Recent SEC Filing	Jan. 05	MT
Intellia Therapeutics, Inc. Announces Resignation of John F. Crowley from the Board of Directors of Company and Its Committees	Dec. 06	CI
Intellia Therapeutics Files Mixed Shelf	Nov. 27	MT
Intellia Therapeutics Receives EU Orphan Drug Designation for Hereditary Angioedema Candidate Therapy	Nov. 14	MT

Chart Intellia Therapeutics, Inc.

Duration

Period

More charts

Company Profile

Intellia Therapeutics, Inc. is a clinical-stage genome editing company, which is focused on developing curative therapeutics using Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) technology. CRISPR/Cas9 is a technology for genome editing, the process of altering selected sequences of genomic deoxyribonucleic acid. It is focused on leveraging its modular platform to advance in vivo and ex vivo therapies for diseases with high unmet need. Its lead in vivo candidate, NTLA-2001, is for the treatment of transthyretin (ATTR) amyloidosis, as well as NTLA-2002 for the treatment of hereditary angioedema (HAE) are the first CRISPR/Cas9-based therapy candidates to be administered systemically, via intravenous (IV) infusion, for precision editing of a gene in a target tissue in humans. It is also developing ex vivo applications to address immuno-oncology and autoimmune diseases.

Sector

Biotechnology & Medical Research

Calendar

2024-06-02 - European Academy of Allergy and Clinical Immunology Congress

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Intellia Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

26.22 USD

Average target price

70.26 USD

Spread / Average Target

+167.96%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
INTELLIA THERAPEUTICS, INC.	-14.00%	2.53B
MODERNA, INC.	+29.77%	49.46B
IQVIA HOLDINGS INC.	+1.00%	42.58B
LONZA GROUP AG	+50.47%	42.49B
CELLTRION, INC.	-5.26%	29.09B
ICON PUBLIC LIMITED COMPANY	+13.68%	26.61B
ALNYLAM PHARMACEUTICALS, INC.	-22.99%	18.64B
BIO-TECHNE CORPORATION	+8.22%	13.16B
MEDPACE HOLDINGS, INC.	+32.41%	12.55B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.62%	11.98B

Other Biotechnology & Medical Research